Nab-PCE vs PC for MM After Failure of Anti-PD-1

Phase 2

• Conditions: Advanced Melanoma
• Interventions: Drug: chemotherapy; Drug: Chemotherapeutic Combinations

• Registration Number: NCT03917069
• Lead Sponsor: Peking University Cancer Hospital & Institute

Brief Summary

This is a randomized controlled clinical trial of nab-paclitaxel + carboplatin

* Endostatin for advanced melanoma after failure of PD-1 therapy. The aim was to evaluate the efficacy and safety of nab-paclitaxel+carboplatin

* endostatin versus combination of paclitaxel and carboplatin in patients with advanced melanoma after failure of PD-1 therapy.

Detailed Description

The enrollment time is expected to be 1.5 year and the observation time is 2 years. The regimen were performed on a 28-day/21-day cycle respectively. Subjects who met the entry criteria were treated in a 2:1 group according to a randomized list: the treatment group was treated with nab-paclitaxel + carboplatin + endostatin regimen, and the control group was treated with paclitaxel + carboplatin. In this trial, the efficacy is evaluated every 8 weeks until disease progression or unacceptable toxicity,or until the investigator deemed that the patient's condition was unacceptable for further treatment. The follow-up period was 24 months after the end of treatment (follow-up patient survival information and new anti-tumor treatment). The planning enrolled sample size for nab-paclitaxel + carboplatin + endostatin group and paclitaxel-carboplatin group were 90 patients and 45 patients, respectively.

Study Timeline

• Study Start: 2019-03-23
• Status Verified: 2019-04
• Study First Submitted: 2019-04-12
• Study First Submitted QC: 2019-04-15
• Last Update Submitted: 2019-04-15
• Study First Posted: 2019-04-16
• Last Update Posted: 2019-04-17
• Primary Completion: 2021-09-30
• Study Completion: 2022-09-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 145

Inclusion Criteria

1. Age ≥ 18 years old, ≤ 70 years old, male or female;
2. Histological or pathological diagnosis of advanced melanoma, and progressed after anti-PD-1 treatment (disease progression or unacceptable toxicity);
3. The patient has at least one (RECIST 1.1 standard) measurable lesion, which needs to be detected by spiral CT or MRI, and the tumor lesion has at least one single diameter ≥ 1 cm;
4. ECOG PS is 0 or 1 (see Annex 1 for standards);
5. The estimated survival period is ≥12 weeks;
6. no chemotherapy contraindications, including normal peripheral blood, liver and kidney function and electrocardiogram are basically normal; Peripheral blood: neutrophils ≥1.5×109/L, platelets≥90×109/ L, hemoglobin≥90 g/L; Renal function: normal serum creatinine; For patients with non-metastatic liver function impairment: alanine, aspartate aminotransferase ≤ 2.5 ULN, For patients with metastatic liver dysfunction: alanine, aspartate aminotransferase ≤ 5 ULN;
7. Patients who have undergone topical treatment for asymptomatic brain metastases can be enrolled and have a clinical stable status of at least 4 weeks.
8. Patients voluntarily participate in and sign an informed consent form.
9. contraindications for the use of no carboplatin, paclitaxel, entropic and albumin paclitaxel

Exclusion Criteria

1. Known HIV, hepatitis B/C virus positive status or history of active tuberculosis (testing prior to randomisation is not required)
2. Received any investigational drug within 28 days or 5 half-lives of the planned first dose of this study treatment.
3. Active infection requiring systemic therapy.
4. A known history of another malignancy or concurrent malignancy unless the patient is disease-free for a minimum of 1 year, is completely treated and is at low-risk of recurrence.
5. Patients with a history or evidence of cardiovascular risk,
6. History or evidence of interstitial lung disease or active non-infectious pneumonitis.
7. Serious or unstable pre-existing medical conditions or other conditions that could interfere with the patient's safety, consent, or compliance.
8. Pregnant or breastfeeding females, or expecting to conceive or father children within the projected period of study treatment (52 weeks followed by 4 months following end of study treatment).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
paclitaxel+carboplatin	chemotherapy	paclitaxel+carboplatin paclitaxel 175 mg/m2, d1+ Carboplatin AUC=5, d1 q21d
nab-paclitaxel + endostatin+ carboplatin	Chemotherapeutic Combinations	nab-paclitaxel + endostatin+ carboplatin nab-paclitaxel 260mg/m2, d1 +Carboplatin AUC=5, d1 +endostatin 15mg, d1-14 q28d

Primary Outcome Measures

Name	Time	Method
Progression free survival (PFS)	3 years	The time from treatment to tumor progression or death

Secondary Outcome Measures

Name	Time	Method
overall survival (OS)	3 years	OS was defined as the time from the date of the first administration of trial regimen to the date of death from any cause (event) or last follow-up (censored data).
Disease Control Rate (DCR)	At the end of Cycle 2 (each cycle is 28 days)	The disease control rate was the proportion of patients with complete remission, partial remission and stability (SD) in all patients.
Objective response rate (ORR)	At the end of Cycle 2 (each cycle is 28 days)	response evaluation disease progression defined by Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) criteria.; response (PR), refers to the number of cases with complete and partial response after treatment as a percentage of the total number of evaluable cases
Adverse events (AE)	3 years	Adverse events (AE) were monitored on an ongoing basis and classified according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0. Patients were assessed for toxicities before each administration, and toxicity was graded accordingly

Trial Locations

Locations (1)

Beijing Cancer Hospital; 🇨🇳 Beijing, Beijing, China